Seven out of 67 children who were given bluebird bio’s (NASDAQ:BLUE) gene therapy Skysona during clinical trials ended up ...

Whilst the events do not outline any new safety risks, the data gives a new understanding of the link between oncogenesis and ...

Seven young boys treated with bluebird bio’s gene therapy for a rare neurological disease have been diagnosed with blood ...

Pfizer shared that the combination of its drugs Talzenna and Xtandi extended survival in men with metastatic ...

A Bluebird Bio gene therapy has helped children with a devastating neurological disorder, but seven have developed blood ...

The recent publication in the New England Journal of Medicine highlighting an increased incidence of hematologic cancers in patients treated with Bluebird Bio’s Skysona product has raised concerns.

Seven young boys given Bluebird's Skysona later developed blood cancers, findings that could shape how doctors balance the gene therapy’s risks against its benefit.

Before the development of Skysona, a bone marrow transplant was their only hope: “When successful, the transplant can also cure the disease. The problem is that in most cases the operation ...

Bluebird bio announces restructuring plans to reduce costs by 20% and achieve cash flow break-even by late 2025. The ...

While the use of elivaldogene autotemcel (eli-cel; Skysona) gene therapy has demonstrated long-term efficacy in patients with ...

(BLUE) plans to reduce workforce by 25%, optimize cost structure, focus on commercial launches, and aim for cash flow ...

The company has not yet seen the financial payoff from its scientific breakthroughs — and it says it is continuing to lose ...